Trifluoperazine and Doxorubicin: Inducing Drug Resistance in Cancer Cells
Author Information
Author(s): N. Kamath, D. Grabowski, J. Ford, R. Ganapathi
Primary Institution: Cleveland Clinic Foundation
Hypothesis
Can trifluoperazine in combination with doxorubicin induce the selection of multidrug resistant tumor cells?
Conclusion
The study found that trifluoperazine combined with low doses of doxorubicin can lead to the selection of tumor cells that are over 30 times more resistant to the drug.
Supporting Evidence
- Trifluoperazine combined with doxorubicin led to a significant increase in drug resistance in L1210 mouse leukemia cells.
- L1210/DT cells showed over 30-fold resistance to doxorubicin after treatment with trifluoperazine.
- Drug accumulation studies indicated that L1210/DT cells retained less doxorubicin compared to sensitive cells.
Takeaway
This study shows that a drug called trifluoperazine can help cancer cells become resistant to another drug called doxorubicin, making it harder to treat the cancer.
Methodology
L1210 mouse leukemia cells were treated with doxorubicin and trifluoperazine, and their resistance was assessed through cytotoxicity assays and drug accumulation studies.
Limitations
The study primarily focuses on a specific cell line and may not fully represent the complexity of drug resistance in all cancer types.
Want to read the original?
Access the complete publication on the publisher's website